Improvement in symptoms and signs in the forefoot of patients with rheumatoid arthritis treated with anti-TNF therapy

Catherine J Bowen*†1,7, Christopher J Edwards4,2,6,5, Lindsey Hooper†1,5, Keith Dewbury†3, Madeleine Sampson†3, Sally Sawyer†4, Jane Burridge†1 and Nigel K Arden†4,6,7

Abstract
Background: Inhibition of tumour necrosis factor (TNF) is an effective way of reducing synovitis and preventing joint damage in rheumatoid arthritis (RA), yet very little is known about its specific effect on foot pain and disability. The aim of this study was to evaluate whether anti-TNF therapy alters the presence of forefoot pathology and/or reduces foot pain and disability.

Methods: Consecutive RA patients starting anti-TNF therapy (infliximab, etanercept, adalimumab) were assessed for presence of synovial hypertrophy and synovitis in the 2nd and 5th metatarso-phalangeal (MTP) joints and plantar forefoot bursal hypertrophy before and 12 weeks after therapy. Tender MTP joints and swollen bursae were established clinically by an experienced podiatrist and ultrasound (US) images were acquired and interpreted by a radiologist. Assessment of patient reported disease impact on the foot was performed using the Manchester Foot Pain and Disability Index (MFPDI).

Results: 31 patients (24 female, 7 male) with RA (12 seronegative, 19 seropositive) completed the study: mean age 59.6 (SD 10.1) years, disease duration 11.1 (SD 10.5) years, and previous number of Disease Modifying Anti Rheumatic Drugs 3.0 (1.6). Significant differences after therapy were found for Erythrocyte Sedimentation Rate (t = 4.014, p < 0.001), C-reactive protein (t = 3.889, p = 0.001), 28 joint Disease Activity Score (t = 3.712, p = 0.0001), Visual Analog Scale (t = 2.735, p = 0.011) and Manchester Foot Pain and Disability Index (t = 3.712, p = 0.001).

Presence of MTP joint synovial hypertrophy on US was noted in 67.5% of joints at baseline and 54.8% of joints at twelve weeks. Presence of plantar forefoot bursal hypertrophy on US was noted in 83.3% of feet at baseline and 75% at twelve weeks. Although there was a trend for reduction in observed presence of person specific forefoot pathology, when the frequencies were analysed (McNemar) this was not significant.

Conclusions: Significant improvements were seen in patient reported foot pain and disability 12 weeks after commencing TNF inhibition in RA, but this may not be enough time to detect changes in forefoot pathology.

Background
Tumour Necrosis Factor (TNF) inhibition is known to be an effective way of reducing synovial hypertrophy and preventing erosions in patients who have rheumatoid arthritis (RA) [1,2]. Unfortunately studies to date have tended to focus on the hand joints and little is known of the effect of TNF inhibition on the foot.

Prevalence rates for pain and swelling in the feet in RA are high [3] and this correlates with patient reported outcome measures of impairment, activity limitation and participation restriction [4]. In fact, most patients with RA continue to report frequent and disabling foot pain despite pharmacological management, including TNF inhibition [5-8]. We have previously reported higher prevalence rates of forefoot pathology detectable by ultrasound (US) than by clinical examination [9]. Clinical assessment techniques are relatively insensitive in assessment of RA disease
within the foot, and clinically under reported manifestations of RA within the foot appear to be a common finding in imaging studies [10-12]. Although investigators have reported the demographic of TNF inhibition, none have formally assessed the effects on foot symptoms and pathology.

US is beneficial in monitoring the progression of active inflammation in rheumatoid arthritis [13] and in the monitoring of biologic therapy [14-16]. The aim of this study was to evaluate by means of US, the effects of anti-TNF therapy in RA patients with specific focus on the forefoot using the hypothesis that forefoot symptoms, like those of hand joint symptoms, would improve with this intervention.

Methods
A prospective study design was utilized, in which the forefeet of a consecutive cohort of patients with RA diagnosed according to the ACR criteria (modified 1987) [17] starting anti-TNF therapy (infliximab, etanercept or adalimumab) was examined clinically and by US at baseline and twelve weeks following therapy.

Participant selection
Participants were recruited from patients with RA attending the Rheumatology Department, Southampton University Hospitals NHS Trust who were starting anti-TNF therapy. In compliance with the declaration of Helsinki, Local Research Ethics Committee approval and informed consent was secured prior to data collection.

We enrolled consecutive patients with RA who were about to start anti-TNF therapy and were considered appropriate for this study. Our recruitment criteria excluded any patients from the study if they had a history of previous forefoot surgery, received a corticosteroid injection to the forefoot within the 3 months prior to this study, had an additional musculoskeletal disease (e.g. primary osteoarthritis, gout, Paget’s disease, systemic lupus erythematosus), or had a serious medical (other than RA) or psychological disorder that would prevent completion of the study protocol.

Data collection
Data collection took place between February 2005 and June 2007. The longer time allowed for sufficient numbers to be recruited as only a limited number of patients were starting anti-TNF therapy during that period. All clinical assessments took place within the Wellcome Trust Clinical Research Facility, Southampton General Hospital. All US scans were undertaken by a Radiologist (KD or MS) and took place in the Department of Radiology, Southampton General Hospital. On each visit, the same treatment bays and US facilities were utilised. An experienced podiatrist assessed both forefeet of all participants (CJB) and the presence of any swelling and/or tenderness was recorded. To reduce recall bias, all investigators (CJE, SB, CJB, KD and MS) were blinded to each other’s results and all were blinded to their own baseline assessment of the individual patient being assessed.

Assessment of demographic and clinical characteristics
Prior to data collection, the diagnosis of RA was confirmed by the supervising consultant (CJE). Following acceptance into the study all participants were assessed by a trained specialist rheumatology nurse (SB) and Disease Activity Scores (DAS-28) were calculated [18].

General demographic and clinical data of age, gender, disease duration, presence of rheumatoid factor, current medication, and current and previous use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) were obtained from the Rheumatology Department database and clinical notes.

Clinical characteristics included visual analog scale (VAS 100 mm) assessment for the patient’s global impression of health, and assessment of disease activity by the number of painful, tender and swollen joints calculated as Disease Activity Scores (DAS-28).

Foot assessments
Foot symptoms were determined by the use of a validated patient administered index, the Manchester Foot Pain and Disability Index (MFPDI) [19]. The MFPDI asked participants to rate a series of 19 questions and took approximately five minutes for participants to complete. The forefeet of all participants were assessed by an experienced podiatrist (CJB) for MTP joint synovitis and plantar forefoot bursitis. All foot assessments were conducted at the same time as the US scans.

Other clinical data
Laboratory assessments included blood tests for C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR) on the same day as the foot assessments and US scans.

Imaging data
US examinations were performed using a Philips HDI 5000 System (Royal Philips Electronics, Netherlands) in B-Mode using a 5-10 MHz linear probe. Images were recorded in two perpendicular planes, longitudinal and transverse and performed moving from proximal to distal as suggested by the EULAR (European League against Rheumatism) working group for musculoskeletal US in rheumatology guidelines [20]. A dorsal approach to detect MTP joint synovial hypertrophy, synovitis and erosion with the patient in a supine position was also
adopted as recommend by the EULAR guidelines, [21] (see Figure 1a).

Observations of MTP joint synovial hypertrophy, synovitis and erosions by US (grey scale and power Doppler where possible) were conducted within just two joints in each foot (second and fifth MTP joints) from both a plantar and dorsal approach. Synovial hypertrophy, synovitis and erosions were registered as being present or absent. We have previously reported on the selection of the second and fifth MTP joints as being representative of the forefoot joints [22] and this has also been corroborated by others more recently [23]. On US synovial hypertrophy appears as hypoechoic intra-articular tissue [24] and if this is inflammatory active synovitis, it shows as a positive power Doppler US signal which gives a colour spectral map superimposed onto the grey scale image [25]. Any synovial hypertrophy, synovitis and erosion within the second and fifth MTP joints identified by US were recorded on a data sheet.

At the time of this study there was no standard definition for imaging of clinically apparent plantar forefoot bursal swelling by US. We therefore decided to use a plantar approach as we were interested in determining the prevalence of bursal hypertrophy within the plantar forefoot region. Two types of bursal hypertrophy may occur within the plantar forefoot region, intermetatarsal or sub-metatarsal. Intermetatarsal bursal hypertrophy appears on US as a well defined fluid collection with hypoechoic or anechoic zones usually bulging more than 1 mm under the metatarsal head level [10,26]. Sub-metatarsal bursal hypertrophy is attributed to adventitial bursitis and defined on US as anechoic or heterogenous collections of fluid within the sub-metatarsal fat pad [26].

For each plantar scan the transducer was placed transversely and moved laterally from the first MTP joint with its centre at the level of the metatarsal heads (see Figure 1b). The process was repeated longitudinally (see Figure 1c). The presence of bursal hypertrophy across the plantar forefoot region identified by US was recorded on a data sheet.

Statistical analyses
Data evaluation and statistical analysis were performed using SPSS version 17.0 software (SPSS, Chicago IL). The data was initially examined using histograms and scatter plots to identify ‘outliers’ that may have occurred due to data entry bias or normal biological outliers. The prevalence of MTP joint synovial hypertrophy, synovitis, erosions and plantar bursal hypertrophy per foot and per anatomical site within the forefoot is described via the mean, standard deviations and frequencies. Paired t-tests for parametric continuous data were performed to determine whether there were differences in patient reported foot pain and disability (MFPDI) between baseline and twelve weeks as well as the clinical variables, ESR, CRP, global well-being (VAS) and DAS-28. To determine change in the presence of forefoot pathology, the presence of MTP joints with synovial hypertrophy, MTP joints with synovitis, and total numbers of plantar forefoot bursal hypertrophy per foot were tested for differences using a McNemar test for categorical data of related groups.
Results

Participant demographics and clinical characteristics
From thirty two patients with RA, starting anti-TNF therapy recruited, one patient was excluded at the baseline visit due to having the wrong diagnosis and one was excluded from the US foot scans due to having open wounds on the plantar forefoot area. Four participants did not return for the ultrasound scans at the twelve week visit (see Figure 2). We did not exclude anyone at the initial participant recruitment session; however a small number of individuals did decline to take part in the study. Thirty one patients therefore started the study, 24 female and 7 male patients, 12 rheumatoid-factor negative and 19 rheumatoid-factor positive. The majority of participants had established RA with a mean age of 59.58 (SD 10.14; range 37-76) years, and duration of RA 11.1 (SD 10.52; range 1-39) years. In line with NICE guidance [27], all had previously been taking DMARDs, (mean 3.0, SD 1.6, per person). A comparison of demographic and clinical characteristics at baseline and twelve weeks can be seen in Table 1.

There was a statistically significant reduction in patient reported foot pain and disability after twelve weeks of anti-TNF therapy (t = 3.712, p = 0.001). Similarly all other clinical disease measures were significantly reduced: ESR (t = 4.014, p < 0.001), CRP (t = 3.889, p = 0.001), DAS-28 (t = 3.712, p = 0.001) and global wellbeing VAS (t = 2.7351, p = 0.011).

Prevalence of forefoot pathology in patients with RA detected by US

At both baseline and twelve weeks a higher prevalence of forefoot pathology per individual was detected by US than by clinical examination (see Table 2). There was an observed trend for reduction in presence of person specific US detectable plantar forefoot bursal hypertrophy and MTP joint synovial hypertrophy between baseline and twelve weeks (see Figure 3).

Observed presence of MTP joint synovial hypertrophy by US from 60 feet (N = 120 joints) indicates presence in 67.5% (81/120 joints) at baseline and 54.8% (57/104 joints) at twelve weeks. At twelve weeks 25.9% (27/104 joints) had changed from MTP joint synovial hypertrophy being present to absent, and 13.5% (14/104 joints) changed from MTP joint synovial hypertrophy being absent to present.

For presence of synovitis detectable by US Doppler, from 44 feet (N = 16 data missing) 10.2% (9/88 joints) was noted at baseline and 6.9% (5/72 joints from 36 feet was noted at twelve weeks. Of these, 11.1% (8/72 joints) had changed from MTP joint synovitis being present to absent and small number, 5.6% (4/72 joints) had changed from MTP joint synovitis being absent to present at twelve weeks.

Frequency of observed presence of US detectable plantar forefoot bursal hypertrophy was higher than that noted in MTP joint synovial hypertrophy but changes followed a similar pattern. US detectable forefoot bursal hypertrophy was noted in 83.3% (50/60) of feet at baseline and 75% (39/52) of feet at twelve weeks. At twelve weeks 19.2% (10/52) of feet had changed from US detectable forefoot bursal hypertrophy being present to absent and 9.6% (5/52) changed from US detectable forefoot bursal hypertrophy being absent to present.

When the frequencies for joint specific and foot specific presence of US and clinically detectable MTP joints with synovial hypertrophy, MTP joints with synovitis, and plantar forefoot bursal hypertrophy per individual were analysed no significant differences were found between the baseline data and twelve weeks (Table 2).

Discussion
To our knowledge, our results are the first to show that patient reported foot pain and disability reduces significantly following TNF inhibition. Furthermore, using US, our results indicate that there is a trend towards reduction in US detectable MTP joint synovial hypertrophy, synovitis and plantar forefoot bursal hypertrophy per individual were analysed no significant differences were found between the baseline data and twelve weeks (Table 2).

Table 1: Demographic and clinical characteristics of the study participants at baseline and twelve weeks by mean (standard deviation)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline</th>
<th>12 weeks</th>
<th>Statistical Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>MFPDI (×/38)</td>
<td>23.17 (9.23)</td>
<td>17.13 (9.73)</td>
<td>t = 3.712, p = 0.001</td>
</tr>
<tr>
<td>VAS* (100 mm)</td>
<td>60.29 (21.12)</td>
<td>45.31 (23.25)</td>
<td>t = 2.735, p = 0.011</td>
</tr>
<tr>
<td>ESR (mm/hour)</td>
<td>37.86 (24.48)</td>
<td>26.5 (16.4)</td>
<td>t = 4.014, p &lt; 0.001</td>
</tr>
<tr>
<td>CRP (mg/litre)</td>
<td>31.92 (27.15)</td>
<td>13.98 (15.38)</td>
<td>t = 3.889, p = 0.001</td>
</tr>
<tr>
<td>DAS-28</td>
<td>5.76 (0.93)</td>
<td>4.54 (1.5)</td>
<td>t = 3.712, p = 0.001</td>
</tr>
</tbody>
</table>

*Overall well being
Consecutive patients with RA who were about to start anti-TNF therapy were recruited between February 2005–June 2007

32 responders

31 participants recruited into the study

31 participants completed all demographic and clinical assessments

30 participants completed all US scans

22 participants completed all Doppler US scans

26 returnees at 12 weeks

26 participants completed all US scans

18 participants completed all Doppler US scans

12 replied with definite no, did not want to take part

1 responded yes but then was excluded during the baseline assessment due to having psoriatic arthritis

1 excluded due to open foot wounds

N=8 missing data for Doppler scans

2 withdrew after baseline assessments due to being too ill to attend

2 withdrew after baseline assessments due to personal reasons

Figure 2 Participant recruitment flow chart of returnees and non returnees at baseline and twelve weeks
effective in controlling the disease process in the RA participants within this study, consistent with previous reports [1,2].

Pragmatically, whilst patient reported foot symptoms did significantly reduce, it may be hypothesized that treatment switches off the disease process of RA, but twelve weeks was not enough time for sonographic evidence of MTP joint synovitis, synovial hypertrophy and plantar bursal hypertrophy to regress within the forefeet. In previous work, within the MCP joints of the hands a reduction in sonographically detectable synovial hypertrophy was noted at eighteen weeks following infliximab therapy, and this was reported as a significant reduction at 110 weeks [2]. In explaining US detection of synovitis within joints, Brown et al [28] report that synovium may become chronically thickened and less reversible in established disease. This was typically demonstrated within our sample in which the majority of participants had established RA with a mean duration of 11.1 years. Using Doppler US 11.1% of MTP joints examined that showed a positive US Doppler response at baseline had none after twelve weeks, yet synovial hypertrophy remained evident on US in 54.8% of MTP joints at twelve weeks. This is consistent with a recent study where 42 joints (bilateral glenohumeral, elbows, wrists, MCPs, proximal interphalangeal, knees, tibiotalar, midtarsal and MTPs) were assessed with the most common joints with US detectable synovitis being the wrist, hands and feet and power Doppler US signal occurring less frequently in the MTP joints [29].

Foot symptoms were not inclusion criteria within our study, yet the high prevalence detectable by US was surprising. There are suggestions that clinically evident disease improves more quickly following effective treatment than disease assessed by modern imaging techniques [11]. In a previous study of patients treated with anti-TNF therapy, 90% demonstrated clinical remission at week 14, but none had absence of imaging synovitis [29]. We can infer this from our findings too, whereby a much higher prevalence of US detectable plantar MTP joint synovial hypertrophy and plantar forefoot bursal hypertrophy was evident than that detectable by clinical examination at both baseline and twelve weeks.

Of further note, in a minority of participants, clinical disease activity and well being scores improved but the prevalence of US detectable MTP joint synovial hypertrophy and plantar forefoot bursal hypertrophy increased. This anomalous finding could be attributable to imperfect reproducibility of the US measurements, a reported phenomenon in the use of US [30], although as technol-

### Table 2: Comparison of the prevalence of MTP joint and foot specific US detectable and clinically detectable pathology of the study participants at baseline and twelve weeks by frequency (N)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline</th>
<th>12 weeks</th>
<th>Statistical Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTP joint synovial hypertrophy (US)</td>
<td>R2</td>
<td>58.1% (18)</td>
<td>45.2% (14)</td>
</tr>
<tr>
<td></td>
<td>R5</td>
<td>74.2% (23)</td>
<td>51.6% (16)</td>
</tr>
<tr>
<td></td>
<td>L2</td>
<td>61.3% (19)</td>
<td>35.3% (11)</td>
</tr>
<tr>
<td></td>
<td>L5</td>
<td>67.7% (21)</td>
<td>54.8% (17)</td>
</tr>
<tr>
<td>MTP joint synovitis (Doppler US)</td>
<td>R2</td>
<td>6.5% (2)</td>
<td>6.5% (2)</td>
</tr>
<tr>
<td></td>
<td>R5</td>
<td>9.7% (3)</td>
<td>3.2% (1)</td>
</tr>
<tr>
<td></td>
<td>L2</td>
<td>3.2% (1)</td>
<td>0% (0)</td>
</tr>
<tr>
<td></td>
<td>L5</td>
<td>9.7% (3)</td>
<td>6.5% (2)</td>
</tr>
<tr>
<td>MTP joint erosion (US)</td>
<td>R2</td>
<td>25.8% (8)</td>
<td>25.8% (8)</td>
</tr>
<tr>
<td></td>
<td>R5</td>
<td>74.2% (23)</td>
<td>51.6% (16)</td>
</tr>
<tr>
<td></td>
<td>L2</td>
<td>9.7% (3)</td>
<td>12.9% (4)</td>
</tr>
<tr>
<td></td>
<td>L5</td>
<td>61.3% (19)</td>
<td>58.1% (18)</td>
</tr>
<tr>
<td>Plantar forefoot bursal hypertrophy (US)</td>
<td>R</td>
<td>83.9% (26)</td>
<td>67.7% (21)</td>
</tr>
<tr>
<td></td>
<td>L</td>
<td>80.6% (25)</td>
<td>69.2% (18)</td>
</tr>
<tr>
<td>Clinically detectable plantar forefoot bursae</td>
<td>R</td>
<td>41.9% (13)</td>
<td>32.3% (10)</td>
</tr>
<tr>
<td></td>
<td>L</td>
<td>35.5% (11)</td>
<td>19.4% (6)</td>
</tr>
<tr>
<td>Clinically detectable MTP joint synovitis</td>
<td>R</td>
<td>45.2% (14)</td>
<td>25.8% (8)</td>
</tr>
<tr>
<td></td>
<td>L</td>
<td>25.8% (8)</td>
<td>16.1% (5)</td>
</tr>
</tbody>
</table>

**Key:** R = Right; L = Left; 2 = second MTP joint; 5 = fifth MTP joint
ogy has improved reliability in US techniques have improved [31]. Alternatively, although the MFPDI improves with treatment, the questionnaire is developed for foot complaints in general and does not focus on the forefoot [19]. Therefore it is possible that the difference between self-reported symptoms in US detectable signs in the forefoot may also be attributable to a faster recovery of other foot joints than the MTP joints. Increased mechanical stresses, possibly as mobility improved for those patients, rather than an increase in episodes of synovial hypertrophy and bursal hypertrophy due to the disease process of RA may also be the cause of prolonged US detectable synovial hypertrophy within the forefeet.

Mechanical and gait data would have been useful to explore this concept further. van der Leeden, Steultjens et al [32] demonstrated correlations of radiographic MTP joint deformity with peak pressure and pressure time integrals for the first and fourth MTP joints and correlations of high forefoot pressures with pain in RA participants. In a later systematic review of foot related measures, van der Leeden, Steultjens et al [33] recommend considering both self report and performance based instruments when investigating foot problems associated with RA. We chose to focus on clinical assessment of foot pathology, foot disability and foot pain and no account was taken of the mechanical forces of foot function during gait as this was not feasible within the confines of our study. Others, having investigated the association between foot disabilities, mechanics of function and foot mechanics, recommend that future prediction models may be enhanced by combining imaging based identification of foot pathology with mechanical data [4].

No techniques have yet been developed to detect differences between mechanically related inflamed hypertrophied synovium and active inflammatory synovium related to disease activity in RA within the foot. Brown, Conaghan et al [28] highlight that grey scale US primarily detects hypertrophy of the synovium but does not differentiate between inflammatory and non inflammatory synovitis. For future studies the further use of power Doppler US, Gadolinium enhanced MRI and/or biopsy

Figure 3 A simple bar chart representing the percentages of cases of US detectable forefoot bursal hypertrophy and MTP joint synovial hypertrophy at baseline and following twelve weeks of anti-TNF therapy.
for histological analysis of forefoot pathology would be needed to achieve this as well as the development of a technique that includes the effect of foot mechanics.

This study has several strengths and a number of potential limitations. Strengths include that it was a pragmatic clinical study representative of secondary care in the UK. In addition, a sample of patients with RA at the same stage of treatment was investigated. Furthermore, patient reported clinical outcomes including disease activity and foot specific measures were used.

Potential limitations include the fact the presence of US detectable MTP joint synovitis, synovial hypertrophy and bursal hypertrophy within the forefoot was not validated by any other ‘gold standard’ imaging technique, such as Magnetic Resonance Imaging (MRI) or by histological analysis through biopsy. Soft tissue swelling at the level of the MTP joints in the plantar forefoot area can be related to other pathology such as tenosynovitis or rheumatoid nodules that could be better differentiated using MRI [34,35]. Due to its restricted availability MRI was not feasible for our study. Others have attempted to validate imaging findings using fresh cadavers [36] however this technique was also not a feasible option during our clinical study.

Limitations relating to the sample and time frame also have to be highlighted. The sample was relatively small; therefore generalizability to the whole population of patients with RA needs to be confirmed. The time frame of twelve weeks gave only two points of assessment over a relatively short period. Although providing useful information, more time points over a longer time period would have allowed variations in individual foot states to be monitored more effectively.

Conclusions
We have demonstrated that patient reported foot pain and disability does reduce significantly following twelve weeks of TNF inhibition. We have also provided some evidence that suggests forefoot pathology in RA may improve following a short period of TNF inhibition; however further evidence over a longer time period is required to confirm that this is sustained. The findings further indicate that the use of US imaging of the foot would be more beneficial than clinical examination alone in the refinement of diagnosis and the implementation of effective care pathways for patients who have foot symptoms and are starting TNF inhibition.

List of abbreviations
TNF: Tumour necrosis factor; RA: Rheumatoid arthritis; MTP: Metatarso-phalangeal; US: Ultrasound; MFPDI: Manchester foot pain and disability index; SD: Standard deviation; DMARDs: Disease modifying anti-rheumatic drugs; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; DAS-28: Disease activity score of 28 swollen and tender joints; VAS: Visual analog scale; ACR: American College of Rheumatology; EULAR: European League Against Rheumatism; NICE: The National Institute for Health and Clinical Excellence; MRI: Magnetic resonance imaging.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
CB conceived of the study, carried out the ultrasound foot study of patients with RA treated with anti-TNF therapy, participated in the clinical assessment of foot status and drafted the manuscript. CE participated in the design of the study, carried out the assessment of eligibility of RA patients for anti-TNF therapy and helped to draft the manuscript. LH participated in the data analysis and helped to draft the manuscript. KD and MS participated in the design of the study and performed the US assessments. SS participated in the study design and coordination. JB participated in the design of the study and helped to draft the manuscript. NA participated in the conception and design of the study and helped to draft the manuscript. All authors read and approved the final manuscript.

Author Details
1School of Health Sciences, University of Southampton, Southampton, UK, 2Research Development and Support Unit, University of Southampton, Southampton, UK, 3Ultrasound Department, Department of Radiology, Southampton University Hospitals NHS Trust, Southampton General Hospital, Southampton, UK, 4Department of Rheumatology, Southampton University Hospitals NHS Trust, Southampton General Hospital, Southampton, UK, 5Wellcome Trust Clinical Research Facility, Southampton University Hospitals Trust, Southampton General Hospital, Southampton, UK, 6MRC Epidemiology Resource Centre, University of Southampton, Southampton, UK and 7NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK

Received: 1 March 2010 Accepted: 17 June 2010
Published: 17 June 2010

References


